Terlipressin Evidence Guide
Terlipressin (Terlivaz) is FDA-approved for hepatorenal syndrome type 1 - a life-threatening complication of advanced cirrhosis - with Phase 3 data from the CONFIRM trial showing significant reversal of HRS-1 versus placebo. As the first FDA-approved treatment specifically for HRS-1, it represents a meaningful regulatory milestone. Respiratory failure risk in high MELD patients is a real safety consideration that limits its use.
Our Take
Terlipressin (Terlivaz) is FDA-approved for hepatorenal syndrome type 1 - a life-threatening complication of advanced cirrhosis - with Phase 3 data from the CONFIRM trial showing significant reversal of HRS-1 versus placebo. As the first FDA-approved treatment specifically for HRS-1, it represents a meaningful regulatory milestone. Respiratory failure risk in high MELD patients is a real safety consideration that limits its use.
- Best for
- Hepatorenal syndrome type 1 (HRS-1), vasopressin V1 receptor agonism, portal hypertension research
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 1mg IV every 6 hours (HRS-1), titrated based on response and serum creatinine
Benefits and Evidence
- Hepatorenal Syndrome Reversal: Level A, includes human evidence - CONFIRM trial showed significantly higher rate of verified HRS reversal with terlipressin vs placebo (32% vs 17%). Reduces serum creatinine and improves renal function in HRS-1.
- Variceal Bleeding Control: Level A, includes human evidence - Effective for acute control of esophageal variceal hemorrhage. Comparable efficacy to somatostatin analogs with the advantage of bolus dosing.
- Ischemic Complications: Level A, includes human evidence - Vasoconstriction-related ischemic events (cardiac, digital, mesenteric, skin necrosis) reported. Respiratory failure also reported in CONFIRM trial at higher rates than placebo.
Side Effects and Warnings
- Abdominal pain and cramping
- Diarrhea
- Respiratory failure
- Skin necrosis and peripheral ischemia
- Bradycardia
- Hyponatremia
- Serious ischemic events (coronary, peripheral, mesenteric) - contraindicated in significant coronary, peripheral, or mesenteric vascular disease
- Respiratory failure - monitor oxygenation; increased risk in patients with volume overload
Research Dosage References
- <strong>Intravenous injection</strong> - 0.85 mg - Every 6 hours - For hepatorenal syndrome (Terlivaz). May increase to 1.7 mg every 6 hours if serum creatinine has not decreased by >=30% by day 4. Maximum treatment duration: 14 days.
- <strong>Intravenous bolus</strong> - 1-2 mg - Every 4-6 hours - For acute variceal hemorrhage (outside US). Given as slow IV bolus. Duration typically 2-5 days.
Mechanism of Action
Terlipressin acts as a prodrug vasopressin analog with V1a receptor selectivity: 1. Prodrug activation: Triglycyl residues are cleaved by tissue peptidases, slowly releasing active lysine-vasopressin, providing a prolonged duration of action. 2. V1a-preferential vasoconstriction: Causes splanchnic arterial vasoconstriction, reducing portal pressure and redirecting blood flow from the overexpanded splanchnic circulation to the systemic and renal circulations. 3. Renal perfusion improvement: In hepatorenal syndrome, reverses the pathological splanchnic vasodilation and effective arterial underfilling that drives renal vasoconstriction and kidney failure. 4. Portal pressure reduction: Reduces portal venous pressure, making it useful for acute variceal hemorrhage and related complications of portal hypertension.
Legal Status
FDA-approved (September 2022) for hepatorenal syndrome with rapid reduction in kidney function. Marketed as Terlivaz by Mallinckrodt. Used outside the US (as Glypressin) for variceal bleeding for decades.
Primary Sources
- Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome (CONFIRM). N Engl J Med, 2021.
- Terlipressin for hepatorenal syndrome: a systematic review and meta-analysis. Hepatology, 2010.
- Terlipressin versus noradrenaline for hepatorenal syndrome. J Hepatol, 2016.